Review





Similar Products

yervoy  (Bristol Myers)
86
Bristol Myers yervoy
<t>Ipilimumab</t> partially restored T cell activation in non-responder patients with NSCLC treated with pembrolizumab plus chemotherapy PBMC from five non-responder patients were stimulated with pembrolizumab ± ipilimumab, in the presence of anti-CD3 and anti-CD28. (A) UMAP graphs for T lymphocyte populations. (B) Two lymphocyte populations differentially present in the two groups of patients were selected and analyzed for the expression of IFN-γ, granzyme B, and IL-10. (C) Frequency of T lymphocyte populations in each stimulus group. Median and interquartile range are shown. Statistical analysis using the Kruskal-Wallis test.
Yervoy, supplied by Bristol Myers, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ipilimumab/pmc13264123-62-1-3?v=Bristol+Myers
Average 86 stars, based on 1 article reviews
yervoy - by Bioz Stars, 2026-07
86/100 stars
  Buy from Supplier
anticytotoxic t lymphocyte antigen 4 ctla 4 antibody ipilimumab  (Agenus Inc)
86
Agenus Inc anticytotoxic t lymphocyte antigen 4 ctla 4 antibody ipilimumab
<t>Ipilimumab</t> partially restored T cell activation in non-responder patients with NSCLC treated with pembrolizumab plus chemotherapy PBMC from five non-responder patients were stimulated with pembrolizumab ± ipilimumab, in the presence of anti-CD3 and anti-CD28. (A) UMAP graphs for T lymphocyte populations. (B) Two lymphocyte populations differentially present in the two groups of patients were selected and analyzed for the expression of IFN-γ, granzyme B, and IL-10. (C) Frequency of T lymphocyte populations in each stimulus group. Median and interquartile range are shown. Statistical analysis using the Kruskal-Wallis test.
Anticytotoxic T Lymphocyte Antigen 4 Ctla 4 Antibody Ipilimumab, supplied by Agenus Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ipilimumab/pm42314852-49-36-40?v=Agenus+Inc
Average 86 stars, based on 1 article reviews
anticytotoxic t lymphocyte antigen 4 ctla 4 antibody ipilimumab - by Bioz Stars, 2026-07
86/100 stars
  Buy from Supplier
nivolumab plus ipilimumab arm  (Agenus Inc)
86
Agenus Inc nivolumab plus ipilimumab arm
<t>Ipilimumab</t> partially restored T cell activation in non-responder patients with NSCLC treated with pembrolizumab plus chemotherapy PBMC from five non-responder patients were stimulated with pembrolizumab ± ipilimumab, in the presence of anti-CD3 and anti-CD28. (A) UMAP graphs for T lymphocyte populations. (B) Two lymphocyte populations differentially present in the two groups of patients were selected and analyzed for the expression of IFN-γ, granzyme B, and IL-10. (C) Frequency of T lymphocyte populations in each stimulus group. Median and interquartile range are shown. Statistical analysis using the Kruskal-Wallis test.
Nivolumab Plus Ipilimumab Arm, supplied by Agenus Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ipilimumab/pm42305037-21-51-30?v=Agenus+Inc
Average 86 stars, based on 1 article reviews
nivolumab plus ipilimumab arm - by Bioz Stars, 2026-07
86/100 stars
  Buy from Supplier
ipilimumab  (Bristol Myers)
86
Bristol Myers ipilimumab
<t>Ipilimumab</t> partially restored T cell activation in non-responder patients with NSCLC treated with pembrolizumab plus chemotherapy PBMC from five non-responder patients were stimulated with pembrolizumab ± ipilimumab, in the presence of anti-CD3 and anti-CD28. (A) UMAP graphs for T lymphocyte populations. (B) Two lymphocyte populations differentially present in the two groups of patients were selected and analyzed for the expression of IFN-γ, granzyme B, and IL-10. (C) Frequency of T lymphocyte populations in each stimulus group. Median and interquartile range are shown. Statistical analysis using the Kruskal-Wallis test.
Ipilimumab, supplied by Bristol Myers, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ipilimumab/us12653809-1931-7-15?v=Bristol+Myers
Average 86 stars, based on 1 article reviews
ipilimumab - by Bioz Stars, 2026-07
86/100 stars
  Buy from Supplier
exemplary anti ctla4 cias include ipilimumab  (Bristol Myers)
86
Bristol Myers exemplary anti ctla4 cias include ipilimumab
<t>Ipilimumab</t> partially restored T cell activation in non-responder patients with NSCLC treated with pembrolizumab plus chemotherapy PBMC from five non-responder patients were stimulated with pembrolizumab ± ipilimumab, in the presence of anti-CD3 and anti-CD28. (A) UMAP graphs for T lymphocyte populations. (B) Two lymphocyte populations differentially present in the two groups of patients were selected and analyzed for the expression of IFN-γ, granzyme B, and IL-10. (C) Frequency of T lymphocyte populations in each stimulus group. Median and interquartile range are shown. Statistical analysis using the Kruskal-Wallis test.
Exemplary Anti Ctla4 Cias Include Ipilimumab, supplied by Bristol Myers, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ipilimumab/us12648943-363-0-5?v=Bristol+Myers
Average 86 stars, based on 1 article reviews
exemplary anti ctla4 cias include ipilimumab - by Bioz Stars, 2026-07
86/100 stars
  Buy from Supplier
ipilimumab nivolumab  (Bristol Myers)
86
Bristol Myers ipilimumab nivolumab
<t>Ipilimumab</t> partially restored T cell activation in non-responder patients with NSCLC treated with pembrolizumab plus chemotherapy PBMC from five non-responder patients were stimulated with pembrolizumab ± ipilimumab, in the presence of anti-CD3 and anti-CD28. (A) UMAP graphs for T lymphocyte populations. (B) Two lymphocyte populations differentially present in the two groups of patients were selected and analyzed for the expression of IFN-γ, granzyme B, and IL-10. (C) Frequency of T lymphocyte populations in each stimulus group. Median and interquartile range are shown. Statistical analysis using the Kruskal-Wallis test.
Ipilimumab Nivolumab, supplied by Bristol Myers, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ipilimumab/pm42235464-19-16-43?v=Bristol+Myers
Average 86 stars, based on 1 article reviews
ipilimumab nivolumab - by Bioz Stars, 2026-07
86/100 stars
  Buy from Supplier
treg activity with ipilimumab  (Agenus Inc)
86
Agenus Inc treg activity with ipilimumab
<t>Ipilimumab</t> partially restored T cell activation in non-responder patients with NSCLC treated with pembrolizumab plus chemotherapy PBMC from five non-responder patients were stimulated with pembrolizumab ± ipilimumab, in the presence of anti-CD3 and anti-CD28. (A) UMAP graphs for T lymphocyte populations. (B) Two lymphocyte populations differentially present in the two groups of patients were selected and analyzed for the expression of IFN-γ, granzyme B, and IL-10. (C) Frequency of T lymphocyte populations in each stimulus group. Median and interquartile range are shown. Statistical analysis using the Kruskal-Wallis test.
Treg Activity With Ipilimumab, supplied by Agenus Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ipilimumab/pmc13246693-159-1-5?v=Agenus+Inc
Average 86 stars, based on 1 article reviews
treg activity with ipilimumab - by Bioz Stars, 2026-07
86/100 stars
  Buy from Supplier

Image Search Results


Ipilimumab partially restored T cell activation in non-responder patients with NSCLC treated with pembrolizumab plus chemotherapy PBMC from five non-responder patients were stimulated with pembrolizumab ± ipilimumab, in the presence of anti-CD3 and anti-CD28. (A) UMAP graphs for T lymphocyte populations. (B) Two lymphocyte populations differentially present in the two groups of patients were selected and analyzed for the expression of IFN-γ, granzyme B, and IL-10. (C) Frequency of T lymphocyte populations in each stimulus group. Median and interquartile range are shown. Statistical analysis using the Kruskal-Wallis test.

Journal: iScience

Article Title: Circulating cell populations as response predictors and targets to improve immunotherapy in metastatic lung cancer

doi: 10.1016/j.isci.2026.116124

Figure Lengend Snippet: Ipilimumab partially restored T cell activation in non-responder patients with NSCLC treated with pembrolizumab plus chemotherapy PBMC from five non-responder patients were stimulated with pembrolizumab ± ipilimumab, in the presence of anti-CD3 and anti-CD28. (A) UMAP graphs for T lymphocyte populations. (B) Two lymphocyte populations differentially present in the two groups of patients were selected and analyzed for the expression of IFN-γ, granzyme B, and IL-10. (C) Frequency of T lymphocyte populations in each stimulus group. Median and interquartile range are shown. Statistical analysis using the Kruskal-Wallis test.

Article Snippet: Ipilimumab, Yervoy , Bristol-Myers Squibb , N/A.

Techniques: Activation Assay, Expressing